Investors

Kadimastem Granted European Patent for Its IsletRx Treatment for Diabetes

May 15, 2023 at 11:10:42 AM

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation

May 9, 2023 at 6:16:05 AM

Kadimastem Earns FDA IND Approval For its US Phase IIa Clinical Trial with AstroRx® to Treat ALS

March 19, 2023 at 7:43:32 AM

Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for ALS

February 19, 2023 at 10:13:44 AM

Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine

February 15, 2023 at 10:16:24 AM

Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

February 5, 2023 at 8:15:19 AM

Kadimastem Announces it raised appx 7.5 million NIS by rights offering

January 9, 2023 at 2:19:09 PM

Kadimastem and iTolerance’s Proposed Collaboration With Receipt of US $1 Million BIRD Grant

December 20, 2022 at 9:55:35 AM

Kadimastem Receives Approval of Patent registration Used to Develop IsletRx for Diabetes

September 28, 2022 at 6:47:50 AM

Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

August 9, 2022 at 7:36:45 AM

Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement

June 8, 2022 at 6:24:04 AM

Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening

May 30, 2022 at 12:56:40 PM

Kadimastem Expands R&D Program to Include Multiple Sclerosis

May 17, 2022 at 9:00:00 PM

Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority

March 3, 2022 at 1:08:29 PM

Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority

December 13, 2021 at 10:36:37 AM

ILEX Medical to Invest 10 million NIS ($3.2 million)

November 29, 2021 at 12:20:17 PM

We rang the TASE bell today!

November 15, 2021 at 6:28:17 AM

Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement

October 26, 2021 at 5:52:59 AM

Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes

October 12, 2021 at 1:45:54 PM

Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan

July 21, 2021 at 12:46:30 PM

Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article

May 11, 2021 at 11:30:15 AM

Kadimastem Raises NIS 22.3 Million ($6.8 Million)

April 26, 2021 at 7:19:04 AM

Kadimastem Granted a Patent in Israel for the Treatment of ALS

March 9, 2021 at 9:00:16 AM

Kadimastem Announces Executive Management Changes

January 31, 2021 at 10:59:20 AM

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

December 15, 2020 at 1:56:27 PM

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

August 3, 2020 at 7:11:53 AM

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020 at 1:25:35 PM

Kadimastem Announces the Completion of Treatment for Cohort B

July 27, 2020 at 1:25:54 PM

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

July 27, 2020 at 1:27:08 PM

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

July 27, 2020 at 1:28:11 PM

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

November 17, 2019 at 2:10:12 PM

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

July 27, 2020 at 1:30:03 PM

Kadimastem Announces Leadership Changes

May 20, 2019 at 1:09:25 PM

Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®

April 18, 2019 at 1:45:49 PM

Appointment of a new CFO for Kadimastem

March 3, 2019 at 7:44:59 AM

Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A

February 24, 2019 at 7:48:37 AM

2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project

February 17, 2019 at 8:00:17 AM

Kadimastem to be included in the TASE Indices

November 27, 2018 at 10:46:59 AM

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

November 14, 2018 at 2:48:21 PM

Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes

November 12, 2018 at 2:48:44 PM

FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS

November 4, 2018 at 2:47:51 PM

Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:

October 9, 2018 at 9:47:57 AM

Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem

October 2, 2018 at 1:47:28 PM

Kadimastem and The AFDR Selected to Receive a bi-National Grant

July 2, 2018 at 1:47:12 PM

Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial

July 1, 2018 at 1:46:48 PM

Kadimastem was honored with a prize for excellence for the presentation of the company's technology

June 27, 2018 at 1:46:28 PM

Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:

January 7, 2019 at 8:15:36 AM

Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published

June 6, 2018 at 7:21:11 AM

Successful Public Offering for Kadimastem

May 15, 2018 at 7:45:40 AM

Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients

April 26, 2018 at 7:47:21 AM